Literature DB >> 20438987

Management of osteoporosis in CKD Stages 3 to 5.

Patricia L Gordon1, Lynda A Frassetto.   

Abstract

Osteoporosis and chronic kidney disease (CKD) are both common conditions of older adults and both may be associated with substantial morbidity. However, biochemical and histologic changes that occur with progressive kidney disease require specific interventions, some of which may be concordant with osteoporosis management in the general population, whereas others may be less relevant or perhaps even harmful. In this article, we review the diagnosis of and management strategies for osteoporosis in individuals with CKD, placing these into perspective with the recently published KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for treatment of CKD-mineral and bone disorder (CKD-MBD). Specifically, we highlight osteoporosis treatment recommendations by CKD stage and discuss new avenues for osteoporosis treatment that may be useful in individuals with CKD. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20438987     DOI: 10.1053/j.ajkd.2010.02.338

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  10 in total

1.  Use of oral bisphosphonates by older adults with fractures and impaired renal function.

Authors:  Cheryl A Sadowski; Tara Spencer; Nese Yuksel
Journal:  Can J Hosp Pharm       Date:  2011-01

Review 2.  Klotho and kidney disease.

Authors:  Ming-Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  J Nephrol       Date:  2010 Nov-Dec       Impact factor: 3.902

3.  Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.

Authors:  M Ota; M Takahata; T Shimizu; Y Kanehira; H Kimura-Suda; Y Kameda; H Hamano; S Hiratsuka; D Sato; N Iwasaki
Journal:  Osteoporos Int       Date:  2016-12-08       Impact factor: 4.507

Review 4.  Effects of acid on bone.

Authors:  David A Bushinsky; Nancy S Krieger
Journal:  Kidney Int       Date:  2022-03-26       Impact factor: 18.998

5.  Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density.

Authors:  Ben-Chung Cheng; Ying-Chou Chen
Journal:  Clin Rheumatol       Date:  2016-10-18       Impact factor: 2.980

Review 6.  FGF23 associated bone diseases.

Authors:  Eryuan Liao
Journal:  Front Med       Date:  2013-03-09       Impact factor: 4.592

Review 7.  Bisphophonates in CKD patients with low bone mineral density.

Authors:  Wen-Chih Liu; Jen-Fen Yen; Cheng-Lin Lang; Ming-Tso Yan; Kuo-Cheng Lu
Journal:  ScientificWorldJournal       Date:  2013-12-31

Review 8.  Dietary Treatment of Metabolic Acidosis in Chronic Kidney Disease.

Authors:  Roswitha Siener
Journal:  Nutrients       Date:  2018-04-20       Impact factor: 5.717

Review 9.  Review on the Utility of Trabecular Bone Score, a Surrogate of Bone Micro-architecture, in the Chronic Kidney Disease Spectrum and in Kidney Transplant Recipients.

Authors:  Enisa Shevroja; Olivier Lamy; Didier Hans
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-24       Impact factor: 5.555

Review 10.  Bone Quality in Chronic Kidney Disease Patients: Current Concepts and Future Directions - Part II.

Authors:  Kamyar Asadipooya; Mohamed Abdalbary; Yahya Ahmad; Elijah Kakani; Marie-Claude Monier-Faugere; Amr El-Husseini
Journal:  Kidney Dis (Basel)       Date:  2021-04-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.